• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Merus N.V. - Common Shares (NQ: MRUS )

    42.07 -1.03 (-2.39%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Merus N.V. - Common Shares

    < Previous 1 2 3 4 5 Next >
    Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
    From Merus N.V.
    Via GlobeNewswire
    Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
    From Merus N.V.
    Via GlobeNewswire
    Merus Scores Its First FDA Approval For Lung Cancer Drug
    FDA approves Merus' Bizengri as the first treatment for advanced NRG1 fusion-positive cancers. U.S. peak sales are estimated at $16.5 million. 
    Via Benzinga
    Exposures Product Safety
    Jim Cramer: This Health Care Stock Is 'Very, Very Speculative'
    Jim Cramer called Allison Transmission a "storied company... terrific. It does great." 
    Via Benzinga
    Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
    From Merus N.V.
    Via GlobeNewswire
    Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' Pipeline
    Merus partners with Partner Therapeutics for U.S. rights to Zeno in NRG1+ cancer. Updated petosemtamab data emerge as a key focus for analysts. 
    Via Benzinga
    XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024
    From Merus N.V.
    Via GlobeNewswire
    This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
    Via Benzinga
    Merus to Present at Upcoming Investor Conferences
    From Merus N.V.
    Via GlobeNewswire
    Merus Receives FDA extension of PDUFA for zenocutuzumab
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024
    Petosemtamab in 2L+ HNSCC interim clinical data selected for rapid oral presentation 
    From Merus N.V.
    Via GlobeNewswire
    Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference
    From Merus N.V.
    Via GlobeNewswire
    MRUS Stock Earnings: Merus Misses EPS, Misses Revenue for Q2 2024
    MRUS stock results show that Merus missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
    Petosemtamab 1500 mg Q2W confirmed for both 2/3L phase 3 trial (LiGeR-HN2) and 1L trial (LiGeR-HN1) in r/m HNSCC following FDA feedback 
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC
    From Merus N.V.
    Via GlobeNewswire
    Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer
    From Merus N.V.
    Via GlobeNewswire
    Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
    From Merus N.V.
    Via GlobeNewswire
    Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces Pricing of Upsized Public Offering of Common Shares
    From Merus N.V.
    Via GlobeNewswire
    Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
    From Merus N.V.
    Via GlobeNewswire
    Merus N.V. Announces Proposed Public Offering of Common Shares
    From Merus N.V.
    Via GlobeNewswire
    Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
    From Merus N.V.
    Via GlobeNewswire
    Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Crude Oil Rises 1%; Verastem Shares Slide
    Via Benzinga
    Exposures Fossil Fuels
    Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.